Clinical Trial: Treatment for Adolescent Marijuana Abuse

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Behavioral Treatment of Adolescent Marijuana Use

Brief Summary: Marijuana remains the most prevalent illicit substance used by adolescents and the number of adolescents receiving treatment for marijuana abuse more than tripled during the last decade. A small number of clinical trials suggest that family-based and individual interventions have efficacy for treating adolescent substance abuse. However, even with these interventions most adolescents fail to reduce their substance use substantially, thus, there remains much room for improvement of treatment services. The overarching goal of this project is to develop and test novel behavioral treatments to enhance treatment outcome in this important treatment population, and in so doing, learn more about mechanisms of change that have broader implications for addiction science. In our initial Stage IB project "Behavioral Treatment for Adolescent Marijuana Abuse", we created, manualized, and pilot tested a unique contingency-management (CM) intervention that combined abstinence-based voucher incentives with contingency management training for parents. A small randomized, clinical trial provided encouraging results. When added to a commonly used cognitive-behavior therapy, CM improved rates of sustained abstinence during treatment. Adolescents receiving this intervention were less likely to relapse over the 9-month follow-up period, however this finding was not as robust as the observed during treatment effects, most likely due to the small sample size and associated low power to detect effects. Despite strong indicators of the efficacy of this CM intervention, there remained room for improvement in increasing rates of treatment response and reducing rates of relapse. Hypothesized mediators and moderators of change indicated that changes in parenting had direct effects on post-treatment marijuana abstinence outcomes, and that abstinence early in treatment was a robust predictor of the CM treatment effect. This proposal will systematically replicate and extend these findings.

Detailed Summary:
Sponsor: Dartmouth-Hitchcock Medical Center

Current Primary Outcome:

  • Marijuana Abstinence (2 Weeks or Greater) [ Time Frame: Testing done twice weekly for 14 weeks. ]
    Percentage of participants who achieved 2 continuous weeks of marijuana abstinence as verified by twice weekly urine testing during the 14 weeks of treatment.
  • Marijuana Abstinence (4 Weeks or Greater) [ Time Frame: Twice weekly urine tests for 14 weeks. ]
    Percentage of participants who achieved 4 continuous weeks of marijuana abstinence as verified by twice weekly urine testing during the 14 weeks of treatment.


Original Primary Outcome: Marijuana abstinence [ Time Frame: Weekly ]

Current Secondary Outcome: Proportion of Days of Marijuana Abstinence Across All Days of Treatment (14 Weeks) [ Time Frame: This is for the proportion of days abstinent across the entire 14-week treatment period. Self-report data are collected twice weekly during treatment to obtain a cumulative proportion ]

This reflects the mean proportion of days of marijuana abstinence for each participant


Original Secondary Outcome: Days of marijuana use [ Time Frame: Monthly ]

Information By: Dartmouth-Hitchcock Medical Center

Dates:
Date Received: December 21, 2007
Date Started: November 2007
Date Completion:
Last Updated: July 30, 2015
Last Verified: July 2015